Common Variable Immunodeficiency Associated with a De Novo

CVID IKAROS IKZF1 R162Q SARS-CoV-2 T-cell response de novo mutation heterologous vaccine humoral response immune response

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
20 Apr 2022
Historique:
received: 30 03 2022
revised: 15 04 2022
accepted: 18 04 2022
entrez: 14 5 2022
pubmed: 15 5 2022
medline: 15 5 2022
Statut: epublish

Résumé

Common variable immunodeficiency (CVID) comprises a group of diseases with heterogeneous clinical and immunological manifestations. Several mutations have been identified in genes encoding proteins essential for immune function. Our aim was to phenotypically and genotypically characterize a patient diagnosed with CVID and study his response to the SARS-CoV-2 vaccine. We performed a next-generation sequencing analysis, a CMIA, and an ELISA to analyze the humoral and cellular response to the SARS-CoV-2 vaccine, respectively. We also employed flow cytometry and immunoturbidimetry to assess the patient's global immune status. We found a low humoral but positive cellular response to the SARS-CoV-2 vaccine. NGS screening revealed a transition from guanine to adenine at position c.485 of the The R162Q variant of the

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Common variable immunodeficiency (CVID) comprises a group of diseases with heterogeneous clinical and immunological manifestations. Several mutations have been identified in genes encoding proteins essential for immune function. Our aim was to phenotypically and genotypically characterize a patient diagnosed with CVID and study his response to the SARS-CoV-2 vaccine.
METHODS METHODS
We performed a next-generation sequencing analysis, a CMIA, and an ELISA to analyze the humoral and cellular response to the SARS-CoV-2 vaccine, respectively. We also employed flow cytometry and immunoturbidimetry to assess the patient's global immune status.
RESULTS RESULTS
We found a low humoral but positive cellular response to the SARS-CoV-2 vaccine. NGS screening revealed a transition from guanine to adenine at position c.485 of the
CONCLUSIONS CONCLUSIONS
The R162Q variant of the

Identifiants

pubmed: 35566429
pii: jcm11092303
doi: 10.3390/jcm11092303
pmc: PMC9101713
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Investig Allergol Clin Immunol. 2018;28(1):53-56
pubmed: 29461212
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Haematologica. 2018 Apr;103(4):565-574
pubmed: 29519871
Emerg Infect Dis. 2021 Aug;27(8):2174-2178
pubmed: 34102097
J Allergy Clin Immunol. 2021 Sep;148(3):739-749
pubmed: 34087242
J Investig Allergol Clin Immunol. 2020;30(1):14-34
pubmed: 30741636
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
Pediatr Blood Cancer. 2012 Apr;58(4):591-7
pubmed: 21548011
Front Immunol. 2021 Oct 04;12:727850
pubmed: 34671350
Immunol Allergy Clin North Am. 2020 Aug;40(3):461-470
pubmed: 32654692
J Allergy Clin Immunol. 2018 Jan;141(1):432-435.e7
pubmed: 28927821
Clin Gastroenterol Hepatol. 2022 Jan;20(1):162-172.e9
pubmed: 34509643
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
J Allergy Clin Immunol. 2017 Jul;140(1):223-231
pubmed: 27939403
Front Immunol. 2019 Apr 16;10:568
pubmed: 31057532
J Clin Immunol. 2022 Feb;42(2):240-252
pubmed: 34787773
Expert Rev Clin Immunol. 2021 Apr;17(4):407-416
pubmed: 33691560
J Clin Invest. 2018 Jul 2;128(7):3071-3087
pubmed: 29889099
Clin Immunol. 2011 Nov;141(2):161-8
pubmed: 21889412
Curr Opin Immunol. 2021 Oct;72:176-185
pubmed: 34153571
J Allergy Clin Immunol Pract. 2021 Oct;9(10):3575-3583
pubmed: 34182162
J Clin Immunol. 2022 May;42(4):716-727
pubmed: 35290571
N Engl J Med. 2022 Mar 17;386(11):1046-1057
pubmed: 35081293
J Clin Immunol. 2021 Jan;41(1):1-10
pubmed: 33392855
J Allergy Clin Immunol. 2018 Aug;142(2):699-702.e12
pubmed: 29705243
Vaccine. 2016 May 5;34(21):2417-2423
pubmed: 27055021
N Engl J Med. 2016 Mar 17;374(11):1032-1043
pubmed: 26981933
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
Genes Dis. 2019 Oct 15;7(1):26-37
pubmed: 32181273

Auteurs

Irene Díaz-Alberola (I)

Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
Programa de Doctorado en Biomedicina, Universidad de Granada, 18016 Granada, Spain.

Andrea Espuch-Oliver (A)

Hospital General Nuestra Señora del Prado, Talavera de la Reina, 45600 Toledo, Spain.

José María García-Aznar (JM)

Health in Code S. L., 15008 A Coruña, Spain.

Christian Ganoza-Gallardo (C)

Health in Code S. L., 15008 A Coruña, Spain.

María Aguilera-Franco (M)

Servicio de Microbiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.

Antonio Sampedro (A)

Servicio de Microbiología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.

Pilar Jiménez (P)

Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.

Miguel Ángel López-Nevot (MÁ)

Servicio de Análisis Clínicos e Inmunología, Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain.
Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.
Departamento de Bioquímica, Biología Molecular e Inmunología III, Universidad de Granada, 18016 Granada, Spain.

Classifications MeSH